16 research outputs found
Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae
Mass administration of endectocides, drugs that kill
blood-feeding arthropods, has been proposed as a complementary
strategy to reduce malaria transmission. Ivermectin is one of
the leading candidates given its excellent safety profile. Here
we provide proof that the effect of ivermectin can be boosted at
two different levels by drugs inhibiting the cytochrome or ABC
transporter in the mammal host and the target mosquitoes. Using
a mini-pig model, we show that drug-mediated cytochrome P450/ABC
transporter inhibition results in a 3-fold increase in the time
ivermectin remains above mosquito-killing concentrations. In
contrast, P450/ABC transporter induction with rifampicin
markedly impaired ivermectin absorption. The same
ketoconazole-mediated cytochrome/ABC transporter inhibition also
occurs outside the mammal host and enhances the mortality of
Anopheles gambiae. This was proven by using the samples from the
mini-pig experiments to conduct an ex-vivo synergistic bioassay
by membrane-feeding Anopheles mosquitoes. Inhibiting the same
cytochrome/xenobiotic pump complex in two different organisms to
simultaneously boost the pharmacokinetic and pharmacodynamic
activity of a drug is a novel concept that could be applied to
other systems. Although the lack of a dose-response effect in
the synergistic bioassay warrants further exploration, our study
may have broad implications for the control of parasitic and
vector-borne diseases
Fecal occult blood and calprotectin testing to prioritize primary care patients for colonoscopy referral: The advantage study
AbstractColonoscopy is the gold standard for colorectal cancer (CRC) diagnosis and screening, but endoscopy services are usually overburdened. This study aims to investigate the usefulness of fecal hemoglobin (fHb) and calprotectin (FC) for the identification of patients with high probability of CRC who need urgent referral.MethodsIn a multicenter prospective study, we enrolled symptomatic patients referred from primary care for colonoscopy. Prior to bowel preparation, fHb and FC quantitative tests were performed. The diagnostic performance was estimated for each biomarker/combination. We built a multivariable predictive model based on logistic regression, translated to a nomogram and a risk calculator to assist clinicians in the decision‐making process.ResultsThe study included 1224 patients, of whom 69 (5.6%) had CRC. At the fHb cut‐offs of >0 and 10 μg/g, the negative predictive values for CRC were 98.8% (95% confidence interval 97.8%–99.3%) and 98.6% (95%CI 97.7%–99.1%), and the sensitivities were 85.5% (95%CI 75.0%–92.8%) and 79.7% (95%CI 68.3%–88.4%), respectively. When we added the cut‐off of 150 μg/g of FC to both fHb thresholds, the sensitivity of fecal tests improved. In the multivariate logistic regression model, the concentration of fHb was an independent predictor for CRC; age and gender were also independently associated with CRC.ConclusionsfHb and FC are useful as part of a triage tool to identify those symptomatic patients with high probability of CRC. This can be easily applied by physicians to prioritize high‐risk patients for urgent colonoscopy
Clinical and Pathological Characterization of Lynch-Like Syndrome
Background & aims: Lynch syndrome is characterized by DNA mismatch repair (MMR) deficiency. Some patients with suspected Lynch syndrome have DNA MMR deficiencies but no detectable mutations in genes that encode MMR proteins-this is called Lynch-like syndrome (LLS). There is no consensus on management of patients with LLS. We collected data from a large series of patients with LLS to identify clinical and pathology features.
Methods: We collected data from a nationwide-registry of patients with colorectal cancer (CRC) in Spain. We identified patients whose colorectal tumors had loss of MSH2, MSH6, PMS2, or MLH1 (based on immunohistochemistry), without the mutation encoding V600E in BRAF (detected by real-time PCR), and/or no methylation at MLH1 (determined by methylation-specific multiplex ligation-dependent probe amplification), and no pathogenic mutations in MMR genes, BRAF, or EPCAM (determined by DNA sequencing). These patients were considered to have LLS. We collected data on demographic, clinical, and pathology features and family history of neoplasms. The χ2 test was used to analyze the association between qualitative variables, followed by the Fisher exact test and the Student t test or the Mann-Whitney test for quantitative variables.
Results: We identified 160 patients with LLS; their mean age at diagnosis of CRC was 55 years and 66 patients were female (41%). The Amsterdam I and II criteria for Lynch syndrome were fulfilled by 11% of cases and the revised Bethesda guideline criteria by 65% of cases. Of the patients with LLS, 24% were identified in universal screening. There were no proportional differences in sex, indication for colonoscopy, immunohistochemistry, pathology findings, or personal history of CRC or other Lynch syndrome-related tumors between patients who met the Amsterdam and/or Bethesda criteria for Lynch syndrome and patients identified in universal screening for Lynch syndrome, without a family history of CRC.
Conclusions: Patients with LLS have homogeneous clinical, demographic, and pathology characteristics, regardless of family history of CRC
Adiponectin, leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD
[EN] Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease where liver biopsy remains the gold standard for diagnosis. Here we aimed
to evaluate the role of circulating adiponectin, leptin, and insulin-like growth factor
1 (IGF-1) levels as non-invasive NAFLD biomarkers and assess their correlation with
the metabolome.
Materials and Methods: Leptin, adiponectin, and IGF-1 serum levels were measured
by ELISA in two independent cohorts of biopsy-proven obese NAFLD patients and
healthy-liver controls (discovery: 38 NAFLD, 13 controls; validation: 194 NAFLD,
31 controls) and correlated with clinical data, histology, genetic parameters, and
serum metabolomics.
Results: In both cohorts, leptin increased in NAFLD vs. controls (discovery: AUROC
0.88; validation: AUROC 0.83; p < 0.0001). The leptin levels were similar between
obese and non-obese healthy controls, suggesting that obesity is not a confounding
factor. In the discovery cohort, adiponectin was lower in non-alcoholic steatohepatitis
(NASH) vs. non-alcoholic fatty liver (AUROC 0.87; p < 0.0001). For the validation
cohort, significance was attained for homozygous for PNPLA3 allele c.444C (AUROC
0.63; p < 0.05). Combining adiponectin with specific serum lipids improved the assay
performance (AUROC 0.80; p < 0.0001). For the validation cohort, IGF-1 was lower with advanced fibrosis (AUROC 0.67, p<0.05), but combination with international normalized
ratio (INR) and ferritin increased the assay performance (AUROC 0.81; p < 0.01).
Conclusion: Serum leptin discriminates NAFLD, and adiponectin combined with
specific lipids stratifies NASH. IGF-1, INR, and ferritin distinguish advanced fibrosis.CR was funded by FEDER through the COMPETE program
and by national funds through Fundação para a Ciência
e a Tecnologia (PTDC/MED-FAR/29097/2017—LISBOA-01-
0145-FEDER-029097) and by European Horizon 2020 (H2020-
MSCA-RISE-2016-734719). This work was also supported by
Fundação para a Ciência e Tecnologia (PD/BD/135467/2017)
and Portuguese Association for the Study of Liver/MSD
2017. JB was funded by Spanish Carlos III Health Institute
(ISCIII) (PI15/01132, PI18/01075 and Miguel Servet Program
CON14/00129 and CPII19/00008), co-financed by Fondo
Europeo de Desarrollo Regional (FEDER), Instituto de Salud
Carlos III (CIBERehd, Spain), La Caixa Scientific Foundation
(HR17-00601), Fundación Científica de la Asociación Española
Contra el Cáncer, and European Horizon 2020 (ESCALON
project: H2020-SC1-BHC-2018-2020)
The genomic history of the Iberian Peninsula over the past 8000 years
We assembled genome-wide data from 271 ancient Iberians, of whom 176 are from the largely unsampled period after 2000 BCE, thereby providing a high-resolution time transect of the Iberian Peninsula.We document high genetic substructure between northwestern and southeastern hunter-gatherers before the spread of farming.We reveal sporadic contacts between Iberia and North Africa by ~2500 BCE and, by ~2000 BCE, the replacement of 40% of Iberia's ancestry and nearly 100% of its Y-chromosomes by people with Steppe ancestry.We show that, in the Iron Age, Steppe ancestry had spread not only into Indo-European-speaking regions but also into non-Indo-European-speaking ones, and we reveal that present-day Basques are best described as a typical Iron Age population without the admixture events that later affected the rest of Iberia. Additionally, we document how, beginning at least in the Roman period, the ancestry of the peninsula was transformed by gene flow from North Africa and the eastern Mediterranean
Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD
Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease where liver biopsy remains the gold standard for diagnosis. Here we aimed to evaluate the role of circulating adiponectin, leptin, and insulin-like growth factor 1 (IGF-1) levels as non-invasive NAFLD biomarkers and assess their correlation with the metabolome.Materials and Methods: Leptin, adiponectin, and IGF-1 serum levels were measured by ELISA in two independent cohorts of biopsy-proven obese NAFLD patients and healthy-liver controls (discovery: 38 NAFLD, 13 controls; validation: 194 NAFLD, 31 controls) and correlated with clinical data, histology, genetic parameters, and serum metabolomics.Results: In both cohorts, leptin increased in NAFLD vs. controls (discovery: AUROC 0.88; validation: AUROC 0.83; p < 0.0001). The leptin levels were similar between obese and non-obese healthy controls, suggesting that obesity is not a confounding factor. In the discovery cohort, adiponectin was lower in non-alcoholic steatohepatitis (NASH) vs. non-alcoholic fatty liver (AUROC 0.87; p < 0.0001). For the validation cohort, significance was attained for homozygous for PNPLA3 allele c.444C (AUROC 0.63; p < 0.05). Combining adiponectin with specific serum lipids improved the assay performance (AUROC 0.80; p < 0.0001). For the validation cohort, IGF-1 was lower with advanced fibrosis (AUROC 0.67, p < 0.05), but combination with international normalized ratio (INR) and ferritin increased the assay performance (AUROC 0.81; p < 0.01).Conclusion: Serum leptin discriminates NAFLD, and adiponectin combined with specific lipids stratifies NASH. IGF-1, INR, and ferritin distinguish advanced fibrosis
Derivaciones al Servicio de Urgencias del hospital en una población de ancianos residentes: Estudio retrospectivo sobre sus causas y adecuación Hospital transfers from a population of elderly residents: A retrospective study about the causes and suitability
Objetivo: analizar las causas y la adecuación de las derivaciones de ancianos institucionalizados al Servicio de Urgencias del hospital. Método: estudio descriptivo retrospectivo transversal sobre la población de una residencia de la Comunidad de Madrid. Se recogieron datos de 45 pacientes derivados durante el año 2008, con un total de 62 derivaciones. Derivación adecuada o pertinente fue aquella que cumpliera uno de los siguientes criterios: 1) el paciente ingresó o estuvo en observación más de 24 horas; 2) precisó ser valorado por un especialista y/o requirió pruebas diagnósticas no disponibles en el centro; y 3) necesitó tratamiento no disponible en el centro. Análisis estadístico descriptivo. Resultados: el 98,4% de las derivaciones cumplió los criterios de adecuación; 67% Criterio 1,21% Criterio 2 y no otros, y 77,4% Criterio 3. La causa más frecuente de derivación fue la sospecha de fractura poscaída (32,3%). El porcentaje anual de fallecidos (22,38%) fue menor que el observado en otras residencias madrileñas, de ellos, el 15,55% falleció en el hospital.<br>Aim: to analyse the causes and suitability of elderly resident transfers to hospital emergencies service. Methods: a retrospective and descriptive study about the resident population in a Residence of Comunidad de Madrid. We recorded data from 45 patients transferred in 2008, out of a total of 62 transfers. A suitable or appropriate derivation was one fulfilling at least one of the following criteria: 1-the patient was admitted to hospital or stayed in observation for more than 24 hours, 2- the patient had to be seen by a specialist or required a diagnosis test that was not available in the centre, 3- the patient needed treatment that was not available in the centre. The statistical analysis was descriptive. Results: 98.4% of the transfers complied with the suitability criteria: 67% criterion 1,21% criterion 2 but not other and 77% criterion 3. The most frequent cause for transfer was possible bone fracture after fall (32.3%). Annual deceased percentage (22,38%) was minor than observed in other residences in Madrid, 15,55%of them died in hospital
Aberrant timing and oddball detection in schizophrenia: findings from a signed differential mapping meta-analysis
Schizophrenia (SZ) is associated with deficits in both temporal and salience processing. The underlying neurological dysfunctions in both processes, which are interrelated and share neuroanatomical bases, remain poorly understood. The principal objective of this study was to elucidate whether there are any brain regions that show abnormal response during timing and oddball tasks in patients with SZ. To this end, we conducted a signed differential mapping (SDM) meta-analysis of functional magnetic resonance imaging (fMRI) studies assessing abnormal responses elicited by tasks based on the oddball paradigm in patients with SZ. We conducted a similar SDM meta-analysis of neuroimaging studies of timing tasks in SZ. Finally, we undertook a multimodal meta-analysis to detect the common findings of the two previous meta-analyses. We found that SZ patients showed hypoactivation in cortical and subcortical areas related to timing. The dysfunction observed during timing tasks partially coincided with deficiencies in change-detection functions (particularly in the case of preattentional processing in the mismatch negativity response). We hypothesize that a dysfunctional timing/change detection network underlies the cognitive impairment observed in SZ
Clinical and Pathological Characterization of Lynch-Like Syndrome.
Lynch syndrome is characterized by DNA mismatch repair (MMR) deficiency. Some patients with suspected Lynch syndrome have DNA MMR deficiencies but no detectable mutations in genes that encode MMR proteins-this is called Lynch-like syndrome (LLS). There is no consensus on management of patients with LLS. We collected data from a large series of patients with LLS to identify clinical and pathology features. We collected data from a nationwide-registry of patients with colorectal cancer (CRC) in Spain. We identified patients whose colorectal tumors had loss of MSH2, MSH6, PMS2, or MLH1 (based on immunohistochemistry), without the mutation encoding V600E in BRAF (detected by real-time PCR), and/or no methylation at MLH1 (determined by methylation-specific multiplex ligation-dependent probe amplification), and no pathogenic mutations in MMR genes, BRAF, or EPCAM (determined by DNA sequencing). These patients were considered to have LLS. We collected data on demographic, clinical, and pathology features and family history of neoplasms. The χ2 test was used to analyze the association between qualitative variables, followed by the Fisher exact test and the Student t test or the Mann-Whitney test for quantitative variables. We identified 160 patients with LLS; their mean age at diagnosis of CRC was 55 years and 66 patients were female (41%). The Amsterdam I and II criteria for Lynch syndrome were fulfilled by 11% of cases and the revised Bethesda guideline criteria by 65% of cases. Of the patients with LLS, 24% were identified in universal screening. There were no proportional differences in sex, indication for colonoscopy, immunohistochemistry, pathology findings, or personal history of CRC or other Lynch syndrome-related tumors between patients who met the Amsterdam and/or Bethesda criteria for Lynch syndrome and patients identified in universal screening for Lynch syndrome, without a family history of CRC. Patients with LLS have homogeneous clinical, demographic, and pathology characteristics, regardless of family history of CRC
Adiponectin, Leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD
Copyright © 2021 Marques, Afonso, Bierig, Duarte-Ramos, Santos-Laso, Jimenez-Agüero, Eizaguirre, Bujanda, Pareja, Luís, Costa, Machado, Alonso, Arretxe, Alustiza, Krawczyk, Lammert, Tiniakos, Flehmig, Cortez-Pinto, Banales, Castro, Normann and Rodrigues. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease where liver biopsy remains the gold standard for diagnosis. Here we aimed to evaluate the role of circulating adiponectin, leptin, and insulin-like growth factor 1 (IGF-1) levels as non-invasive NAFLD biomarkers and assess their correlation with the metabolome. Materials and Methods: Leptin, adiponectin, and IGF-1 serum levels were measured by ELISA in two independent cohorts of biopsy-proven obese NAFLD patients and healthy-liver controls (discovery: 38 NAFLD, 13 controls; validation: 194 NAFLD, 31 controls) and correlated with clinical data, histology, genetic parameters, and serum metabolomics. Results: In both cohorts, leptin increased in NAFLD vs. controls (discovery: AUROC 0.88; validation: AUROC 0.83; p < 0.0001). The leptin levels were similar between obese and non-obese healthy controls, suggesting that obesity is not a confounding factor. In the discovery cohort, adiponectin was lower in non-alcoholic steatohepatitis (NASH) vs. non-alcoholic fatty liver (AUROC 0.87; p < 0.0001). For the validation cohort, significance was attained for homozygous for PNPLA3 allele c.444C (AUROC 0.63; p < 0.05). Combining adiponectin with specific serum lipids improved the assay performance (AUROC 0.80; p < 0.0001). For the validation cohort, IGF-1 was lower with advanced fibrosis (AUROC 0.67, p < 0.05), but combination with international normalized ratio (INR) and ferritin increased the assay performance (AUROC 0.81; p < 0.01). Conclusion: Serum leptin discriminates NAFLD, and adiponectin combined with specific lipids stratifies NASH. IGF-1, INR, and ferritin distinguish advanced fibrosis.CR was funded by FEDER through the COMPETE program and by national funds through Fundação para a Ciência e a Tecnologia (PTDC/MED-FAR/29097/2017—LISBOA-01-0145-FEDER-029097) and by European Horizon 2020 (H2020-MSCA-RISE-2016-734719). This work was also supported by Fundação para a Ciência e Tecnologia (PD/BD/135467/2017) and Portuguese Association for the Study of Liver/MSD 2017. JB was funded by Spanish Carlos III Health Institute (ISCIII) (PI15/01132, PI18/01075 and Miguel Servet Program CON14/00129 and CPII19/00008), co-financed by Fondo Europeo de Desarrollo Regional (FEDER), Instituto de Salud Carlos III (CIBERehd, Spain), La Caixa Scientific Foundation (HR17-00601), Fundación Científica de la Asociación Española Contra el Cáncer, and European Horizon 2020 (ESCALON project: H2020-SC1-BHC-2018-2020).info:eu-repo/semantics/publishedVersio